U.S. Food and Drug Administration, Center for Drug Evaluation and Research
FDA Drug Safety Podcasts
Rimani informato con discussioni approfondite sugli aggiornamenti sulla sicurezza dei farmaci e le comunicazioni della FDA, aiutandoti a fare scelte migliori per la tua salute e il tuo benessere.
Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis
5 mins • Jan 2, 2025
Charts
- 181NEW
- 159NEW
- 75Decreased by 15
- 73Decreased by 22
- 197Decreased by 12
Episodi recenti
![](https://files.podcastos.com/shows/z9wif3/jpeg256-a9457395.jpg)
Jan 2, 2025
Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis
5 mins
![](https://files.podcastos.com/shows/z9wif3/jpeg256-a9457395.jpg)
Sep 20, 2024
FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause
4 mins
![](https://files.podcastos.com/shows/z9wif3/jpeg256-a9457395.jpg)
Feb 6, 2024
FDA adds Boxed Warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease taking osteoporosis medicine Prolia (denosumab)
4 mins
![](https://files.podcastos.com/shows/z9wif3/jpeg256-a9457395.jpg)
Jan 26, 2024
Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity
4 mins
![](https://files.podcastos.com/shows/z9wif3/jpeg256-a9457395.jpg)
Dec 8, 2023
FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and clobazam (Onfi, Sympazan)
5 mins
![](https://files.podcastos.com/shows/z9wif3/jpeg-c9b62089.jpg)
Lingua
Inglese
Paese
Stati Uniti
Sito web
Feed
Richiedi un aggiornamento
Gli aggiornamenti potrebbero richiedere alcuni minuti.